U.K. Deal Reached For 5-Year Price Cap On State’s Branded Drug Regulation
This article was originally published in The Pink Sheet Daily
The first-ever cap on U.K. National Health Service drug price increases will last five years. Pharma firms reluctantly agreed to the restrictions, but say they are excessive and further undermine Britain’s attractiveness as a place to conduct drug R&D.
You may also be interested in...
Prices may decrease, but at least wider societal benefits are to be included in NICE’s assessment in the U.K.’s new value-based pricing (VBP) scheme for new pharmaceuticals, a change long demanded by critics of the health technology assessment body.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.